Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis

ESC Heart Failure

Volumn 5, Issue 1, 2018, Pages 139-148

  Ferreira, João Pedro ^a,b   Machu, Jean Loup ^a   Girerd, Nicolas ^a   Jaisser, Frederic ^c   Thum, Thomas ^d,e   Butler, Javed ^f   González, Arantxa ^g,h,i   Diez, Javier ^g,h,i   Heymans, Stephane ^j   McDonald, Kenneth ^k   Gyöngyösi, Mariann ^l   Firat, Hueseyin ^m   Rossignol, Patrick ^a   Pizard, Anne ^a   Zannad, Faiez ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b University of Porto   (Portugal)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^f STONY BROOK UNIVERSITY   (United States)

^g UNIVERSITY OF NAVARRA   (Spain)

^h UNIVERSITY CLINIC OF NAVARRA   (Spain)

ⁱ INSTITUTO DE SALUD CARLOS III   (Spain)

^j MAASTRICHT UNIVERSITY   (Netherlands)

^k UNIVERSITY COLLEGE DUBLIN   (Ireland)

^l MEDICAL UNIVERSITY OF VIENNA   (Austria)

^m Firalis SAS   (France)

more..

Author keywords

Fibrotic bioprofiles; Heart failure; Myocardial fibrosis

Indexed keywords

BIOLOGICAL MARKER;

ANIMAL; CARDIAC MUSCLE; CARDIOMYOPATHY; FIBROSIS; HUMAN; METABOLISM; METHODOLOGY; PATHOLOGY;

ANIMALS; BIOMARKERS; CARDIOMYOPATHIES; FIBROSIS; HUMANS; MYOCARDIUM; RESEARCH DESIGN;

EID: 85052854613     PISSN: None     EISSN: 20555822     Source Type: Journal    
DOI: 10.1002/ehf2.12218     Document Type: Article

References (62)

1. Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 2009; 123: 255–278
2. Kong P, Christia P, Frangogiannis N. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci 2014; 71: 549–574
3. Li A-H, Liu PP, Villarreal FJ, Garcia RA. Dynamic changes in myocardial matrix and relevance to disease: translational perspectives. Circ Res 2014; 114: 916–927
4. Weber KT, Pick R, Jalil JE, Janicki JS, Carroll EP. Patterns of myocardial fibrosis. J Mol Cell Cardiol 1989; 21: 121–131
5. Hansen NU, Genovese F, Leeming DJ, Karsdal MA. The importance of extracellular matrix for cell function and in vivo likeness. Exp Mol Pathol 2015; 98: 286–294
6. Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand JL, Cohen-Tervaert JW, Drexler H, Filippatos G, Felix SB, Gullestad L, Hilfiker-Kleiner D, Janssens S, Latini R, Neubauer G, Paulus WJ, Pieske B, Ponikowski P, Schroen B, Schultheiss HP, Tschope C, Van Bilsen M, Zannad F, McMurray J, Shah AM. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009; 11: 119–129
7. Heymans S, Gonzalez A, Pizard A, Papageorgiou AP, Lopez-Andres N, Jaisser F, Thum T, Zannad F, Diez J. Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential. Eur J Heart Fail 2015; 17: 764–771
8. Jacobs L, Thijs L, Jin Y, Zannad F, Mebazaa A, Rouet P, Pinet F, Bauters C, Pieske B, Tomaschitz A, Mamas M, Diez J, McDonald K, Cleland JG, Rocca HP, Heymans S, Latini R, Masson S, Sever P, Delles C, Pocock S, Collier T, Kuznetsova T, Staessen JA. Heart ‘omics’ in AGEing (HOMAGE): design, research objectives and characteristics of the common database. J Biomed Res 2014; 28: 349–359
9. Ferreira JP, Girerd N, Bozec E, Machu JL, Boivin JM, London GM, Zannad F, Rossignol P. Intima-media thickness is linearly and continuously associated with systolic blood pressure in a population-based cohort (STANISLAS Cohort Study). J Am Heart Assoc 2016; 5: pii: e003529
10. Kalogeropoulos A, Psaty BM, Vasan RS, Georgiopoulou V, Smith AL, Smith NL, Kritchevsky SB, Wilson PW, Newman AB, Harris TB, Butler J. Validation of the health ABC heart failure model for incident heart failure risk prediction: the Cardiovascular Health Study. Circ Heart Fail 2010; 3: 495–502
11. Lamblin N, Fertin M, de Groote P, Bauters C. Incidence, determinants and consequences of left atrial remodelling after a first anterior myocardial infarction. Arch Cardiovasc Dis 2012; 105: 18–23
12. Toupance S, Watfa G, Lakomy C, Kearney-Schwartz A, Labat C, Rossignol P, Lacolley P, Zannad F, Benetos A. 2C.01: fixed ranking of leukocyte telomere length in elderly people: results from 8 year follow-up of the Adelahyde cohort. J Hypertens 2015; 33: e25
13. Lemarie J, Huttin O, Girerd N, Mandry D, Juilliere Y, Moulin F, Lemoine S, Beaumont M, Marie PY, Selton-Suty C. Usefulness of speckle-tracking imaging for right ventricular assessment after acute myocardial infarction: a magnetic resonance imaging/echocardiographic comparison within the relation between aldosterone and cardiac remodeling after myocardial infarction study. J Am Soc Echocardiogr 2015; 28: 818–827, e4
14. Ledwidge M, Gallagher J, Conlon C, Tallon E, O'Connell E, Dawkins I, Watson C, O'Hanlon R, Bermingham M, Patle A, Badabhagni MR, Murtagh G, Voon V, Tilson L, Barry M, McDonald L, Maurer B, McDonald K. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 2013; 310: 66–74
15. Zurek M, Maeder MT, Rickli H, Muzzarelli S, Sanders-van Wijk S, Abbuhl H, Handschin R, Jeker U, Pfisterer M, Brunner-la Rocca HP. Differential prognostic impact of resting heart rate in older compared with younger patients with chronic heart failure—insights from TIME-CHF. J Card Fail 2015; 21: 347–354
16. Lopez B, Gonzalez A, Ravassa S, Beaumont J, Moreno MU, San Jose G, Querejeta R, Diez J. Circulating biomarkers of myocardial fibrosis: the need for a reappraisal. J Am Coll Cardiol 2015; 65: 2449–2456
17. Lopez B, Querejeta R, Gonzalez A, Larman M, Diez J. Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure: potential role of lysyl oxidase. Hypertension 2012; 60: 677–683
18. Prockop DJ, Sieron AL, Li SW. Procollagen N-proteinase and procollagen C-proteinase. Two unusual metalloproteinases that are essential for procollagen processing probably have important roles in development and cell signaling. Matrix Biol 1998; 16: 399–408
19. Lopez B, Ravassa S, Gonzalez A, Zubillaga E, Bonavila C, Berges M, Echegaray K, Beaumont J, Moreno MU, San Jose G, Larman M, Querejeta R, Diez J. Myocardial collagen cross-linking is associated with heart failure hospitalization in patients with hypertensive heart failure. J Am Coll Cardiol 2016; 67: 251–260
20. Robins SP. Biochemistry and functional significance of collagen cross-linking. Biochem Soc Trans 2007; 35: 849–852
21. Lopez B, Gonzalez A, Querejeta R, Larman M, Rabago G, Diez J. Association of cardiotrophin-1 with myocardial fibrosis in hypertensive patients with heart failure. Hypertension 2014; 63: 483–489
22. Klappacher G, Franzen P, Haab D, Mehrabi M, Binder M, Plesch K, Pacher R, Grimm M, Pribill I, Eichler HG et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 1995; 75: 913–918
23. Koguchi W, Kobayashi N, Takeshima H, Ishikawa M, Sugiyama F, Ishimitsu T. Cardioprotective effect of apelin-13 on cardiac performance and remodeling in end-stage heart failure. Circ J 2012; 76: 137–144
24. Pchejetski D, Foussal C, Alfarano C, Lairez O, Calise D, Guilbeau-Frugier C, Schaak S, Seguelas MH, Wanecq E, Valet P, Parini A, Kunduzova O. Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1. Eur Heart J 2012; 33: 2360–2369
25. Collinson P. The role of cardiac biomarkers in cardiovascular disease risk assessment. Curr Opin Cardiol 2014; 29: 366–371
26. Lopez B, Gonzalez A, Querejeta R, Zubillaga E, Larman M, Diez J. Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin. Eur J Heart Fail 2015; 17: 385–392
27. Bayes-Genis A, de Antonio M, Vila J, Penafiel J, Galan A, Barallat J, Zamora E, Urrutia A, Lupon J. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol 2014; 63: 158–166
28. Wollert KC, Kempf T, Wallentin L. Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clin Chem 2017; 63: 140–151
29. Savoia C, Touyz RM, Amiri F, Schiffrin EL. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension 2008; 51: 432–439
30. van Deursen VM, Damman K, Voors AA, van der Wal MH, Jaarsma T, van Veldhuisen DJ, Hillege HL. Prognostic value of plasma neutrophil gelatinase-associated lipocalin for mortality in patients with heart failure. Circ Heart Fail 2014; 7: 35–42
31. Eilenberg W, Stojkovic S, Piechota-Polanczyk A, Kaun C, Rauscher S, Groger M, Klinger M, Wojta J, Neumayer C, Huk I, Demyanets S. Neutrophil gelatinase-associated lipocalin (NGAL) is associated with symptomatic carotid atherosclerosis and drives pro-inflammatory state in vitro. Eur J Vasc Endovasc Surg 2016; 51: 623–631
32. Tarin C, Fernandez-Garcia CE, Burillo E, Pastor-Vargas C, Llamas-Granda P, Castejon B, Ramos-Mozo P, Torres-Fonseca MM, Berger T, Mak TW, Egido J, Blanco-Colio LM, Martin-Ventura JL. Lipocalin-2 deficiency or blockade protects against aortic abdominal aneurysm development in mice. Cardiovasc Res 2016; 111: 262–273
33. Hemdahl AL, Gabrielsen A, Zhu C, Eriksson P, Hedin U, Kastrup J, Thoren P, Hansson GK. Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol 2006; 26: 136–142
34. Viereck J, Thum T. Circulating noncoding RNAs as biomarkers of cardiovascular disease and injury. Circ Res 2017; 120: 381–399
35. Watson CJ, Gupta SK, O'Connell E, Thum S, Glezeva N, Fendrich J, Gallagher J, Ledwidge M, Grote-Levi L, McDonald K, Thum T. MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. Eur J Heart Fail 2015; 17: 405–415
36. Derda AA, Thum S, Lorenzen JM, Bavendiek U, Heineke J, Keyser B, Stuhrmann M, Givens RC, Kennel PJ, Schulze PC, Widder JD, Bauersachs J, Thum T. Blood-based microRNA signatures differentiate various forms of cardiac hypertrophy. Int J Cardiol 2015; 196: 115–122
37. Devaux Y, Zangrando J, Schroen B, Creemers EE, Pedrazzini T, Chang CP, Dorn GW 2nd, Thum T, Heymans S. Long noncoding RNAs in cardiac development and ageing. Nat Rev Cardiol 2015; 12: 415–425
38. Summer G, Kelder T, Radonjic M, van Bilsen M, Wopereis S, Heymans S. The Network Library: a framework to rapidly integrate network biology resources. Bioinformatics 2016; 32: i473–i478
39. Summer G, Kelder T, Ono K, Radonjic M, Heymans S, Demchak B. cyNeo4j: connecting Neo4j and Cytoscape. Bioinformatics 2015; 31: 3868–3869
40. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993–1004
41. Swedberg K, Kjekshus J. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Am J Cardiol 1988; 62: 60A–66A
42. Ferreira JP, Girerd N, Rossignol P, Zannad F. Geographic differences in heart failure trials. Eur J Heart Fail 2015; 17: 893–905
43. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O'Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial. Circulation 2015; 131: 34–42
44. Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, Angiolillo DJ, Held C, Cannon CP, James S, Pieper KS, Horrow J, Harrington RA, Wallentin L. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2011; 124: 544–554
45. Pocock S, Calvo G, Marrugat J, Prasad K, Tavazzi L, Wallentin L, Zannad F, Alonso Garcia A. International differences in treatment effect: do they really exist and why? Eur Heart J 2013; 34: 1846–1852
46. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000; 102: 2700–2706
47. Condorelli G, Jotti GS, Pagiatakis C. Fibroblast senescence as a therapeutic target of myocardial fibrosis: beyond spironolactone? J Am Coll Cardiol 2016; 67: 2029–2031
48. Ho JE, Enserro D, Brouwers FP, Kizer JR, Shah SJ, Psaty BM, Bartz TM, Santhanakrishnan R, Lee DS, Chan C, Liu K, Blaha MJ, Hillege HL, van der Harst P, van Gilst WH, Kop WJ, Gansevoort RT, Vasan RS, Gardin JM, Levy D, Gottdiener JS, de Boer RA, Larson MG. Predicting heart failure with preserved and reduced ejection fraction: the International Collaboration on Heart Failure Subtypes. Circ Heart Fail 2016; 9: pii: e003116
49. Ganz P, Heidecker B, Hveem K, Jonasson C, Kato S, Segal MR, Sterling DG, Williams SA. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. Jama 2016; 315: 2532–2541
50. Lopez B, Gonzalez A, Varo N, Laviades C, Querejeta R, Diez J. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 2001; 38: 1222–1226
51. Morillas P, Quiles J, de Andrade H, Castillo J, Tarazon E, Rosello E, Portoles M, Rivera M, Bertomeu-Martinez V. Circulating biomarkers of collagen metabolism in arterial hypertension: relevance of target organ damage. J Hypertens 2013; 31: 1611–1617
52. O'Meara E, Rouleau JL, White M, Roy K, Blondeau L, Ducharme A, Neagoe PE, Sirois MG, Lavoie J, Racine N, Liszkowski M, Madore F, Tardif JC, de Denus S. Heart failure with anemia: novel findings on the roles of renal disease, interleukins, and specific left ventricular remodeling processes. Circ Heart Fail 2014; 7: 773–781
53. Su CT, Liu YW, Lin JW, Chen SI, Yang CS, Chen JH, Hung KY, Tsai WC, Huang JW. Increased procollagen type I C-terminal peptide levels indicate diastolic dysfunction in end-stage renal disease patients undergoing maintenance dialysis therapy. J Am Soc Echocardiogr 2012; 25: 895–901
54. Jellis CL, Sacre JW, Wright J, Jenkins C, Haluska B, Jeffriess L, Martin J, Marwick TH. Biomarker and imaging responses to spironolactone in subclinical diabetic cardiomyopathy. Eur Heart J Cardiovasc Imaging 2014; 15: 776–786
55. Ihm SH, Youn HJ, Shin DI, Jang SW, Park CS, Kim PJ, Kim HY, Chang K, Seung KB, Kim JH, Choi KB. Serum carboxy-terminal propeptide of type I procollagen (PIP) is a marker of diastolic dysfunction in patients with early type 2 diabetes mellitus. In Int J Cardiol, Netherlands 2007; 122: e36–e38
56. Kosmala W, Jedrzejuk D, Derzhko R, Przewlocka-Kosmala M, Mysiak A, Bednarek-Tupikowska G. Left ventricular function impairment in patients with normal-weight obesity: contribution of abdominal fat deposition, profibrotic state, reduced insulin sensitivity, and proinflammatory activation. Circ Cardiovasc Imaging 2012; 5: 349–356
57. Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, Marwick TH. Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade. Heart 2013; 99: 320–326
58. Zhao F, Zhang S, Chen Y, Gu W, Ni B, Shao Y, Wu Y, Qin J. Increased expression of NF-AT3 and NF-AT4 in the atria correlates with procollagen I carboxyl terminal peptide and TGF-beta1 levels in serum of patients with atrial fibrillation. BMC Cardiovasc Disord 2014; 14: 167
59. Zhang SH, Wang J, Jin TR, Zhang LX, Shao J. The role of spironolactone in the metabolism of serum type I collagen in elderly patients with atrial fibrillation. Eur Rev Med Pharmacol Sci 2014; 18: 2903–2907
60. Barthelemy O, Beygui F, Vicaut E, Rouanet S, Van Belle E, Baulac C, Degrandsart A, Dallongeville J, Montalescot G. Relation of high concentrations of plasma carboxy-terminal telopeptide of collagen type I with outcome in acute myocardial infarction. Am J Cardiol 2009; 104: 904–909
61. Li MJ, Huang CX, Okello E, Yanhong T, Mohamed S. Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology. Can J Cardiol 2009; 25: 523–526
62. Meyer K, Hodwin B, Ramanujam D, Engelhardt S, Sarikas A. Essential role for premature senescence of myofibroblasts in myocardial fibrosis. J Am Coll Cardiol 2016; 67: 2018–2028